Endocrine Society celebrates Supreme Court decision to uphold the Affordable Care Act

The Endocrine Society today praised the U.S. Supreme Court’s decision to uphold the Affordable Care Act, which makes health care accessible to millions of individuals nationwide, including those with hormone health conditions such as diabetes, osteoporosis, thyroid conditions, and breast and prostate cancer.

Endocrine Society names new Editors-in-Chief of Endocrine Reviews, Journal of the Endocrine Society

The Endocrine Society appointed two new Editors-in-Chief of its prestigious journals. Ashley Grossman M.D., F.R.C.P., of Barts and the London School of Medicine in London, U.K., has been named the next Editor-in-Chief of Endocrine Reviews, and Zeynep Madak-Erdogan, Ph.D., of the University of Illinois at Urbana-Champaign in Urbana, Ill., has been named as Editor-in-Chief of the Journal of the Endocrine Society (JES).

Drug used during pregnancy may increase cancer risk in mother’s adult children

Exposure in the womb to a drug used to prevent miscarriage appears to raise the offspring’s cancer risk decades later, especially for colorectal and prostate cancers, researchers have found. They will present the results of their new study Tuesday at ENDO 2021, the Endocrine Society’s annual meeting.

High readmission rate found for adults with type 1 diabetes hospitalized for diabetic ketoacidosis

One in five adults with type 1 diabetes who require in-hospital treatment of the life-threatening condition diabetic ketoacidosis has an unplanned repeat hospital visit within a month and is twice as likely to die during the second hospitalization, a new study finds. The results, which will be presented at ENDO 2021, the Endocrine Society’s annual meeting, also identified several factors that increased the readmission risk for these patients.

Genetic evidence suggests men can develop PCOS-like condition

New genetic research suggests men can develop characteristics of polycystic ovary syndrome (PCOS)—a common metabolic and reproductive disorder that affects women. The study was presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Tubeless automated insulin delivery system improves blood glucose outcomes

People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

First targeted therapy for children with achondroplasia shows persistent height gain for up to two years

Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

“Hunger hormone” ghrelin affects monetary decision making

Higher levels of the stomach-derived hormone ghrelin, which stimulates appetite, predict a greater preference for smaller immediate monetary rewards over larger delayed financial rewards, a new study finds. The study results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

Semaglutide reduces excess body fat in people with obesity

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Supplements may protect those with low vitamin D levels from severe COVID-19

Patients with low vitamin D levels who are hospitalized for COVID-19 may have a lower risk of dying or requiring mechanical ventilation if they receive vitamin D supplementation of at least 1,000 units weekly, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Children, teens with type 1 diabetes had better glucose control during COVID-19 lockdown

Blood glucose levels improved among children and teens with type 1 diabetes during the first 12 weeks of COVID-19 lockdown in the United Kingdom, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

New treatment shows promise in preventing heart failure after heart attack

A study in mice finds treatment with a molecule called MCB-613 repairs heart tissue after a severe heart attack, preventing damage that can lead to heart failure. The findings are being presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Night owls with gestational diabetes may face higher risk of pregnancy complications

Among women who develop diabetes during pregnancy, night owls have a higher risk of complications for mother and baby than early birds do, according to a study whose results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

Many endocrine patients, providers want to continue telehealth after pandemic

Two-thirds of patients with chronic endocrine health problems who need close monitoring say they would like to continue with telemedicine follow-up visits after the COVID-19 pandemic ends, according to a survey that will be presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. Three-quarters of providers also said they want to continue with telehealth after the pandemic.

Study finds oral testosterone therapy undecanoate is effective, with no liver toxicity

An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with low testosterone levels, with no evidence of liver toxicity. The findings are being presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Combination thyroid hormone therapies treat hypothyroidism as well as levothyroxine

Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body’s two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Results of their new randomized clinical study are being presented at ENDO 2021, the Endocrine Society’s annual meeting.

U.S. children from Spanish-speaking households experience higher rate of obesity than those from English-speaking families

Nearly one in five U.S. children and teenagers has obesity, and statistics show a higher prevalence of obesity in certain ethnicities, such as Hispanics and Blacks. Now results of a study being presented at ENDO 2021, the Endocrine Society’s annual meeting, suggest that Spanish as a family’s primary language is a predictor of childhood obesity, regardless of ethnicity.

Osteoporosis drug prescribing often does not follow guidelines

Less than one in 10 commercially insured patients in the United States who broke a hip, a major complication of osteoporosis, receive any osteoporosis medical treatment within two calendar quarters of their fracture, according to a study whose results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

Nearly one-third of older thyroid patients take medications that interfere with thyroid function tests

Nearly one-third of adults age 65 and older who take thyroid hormone also take medications that are known to interfere with thyroid function tests, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.

Propylparaben exposure during pregnancy, breastfeeding may reduce protection against breast cancer

Low doses of propylparaben—an estrogen-like chemical used as a preservative in personal care products and foods—can alter pregnancy-related changes in the breast in ways that may reduce the normal protection against breast cancer that pregnancy hormones convey, according to a new study being published in the Endocrine Society’s journal Endocrinology.

Endocrine Society and partners to intervene in U.K. transgender medicine court appeal

The United Kingdom’s High Court has granted permission for a coalition of LGBTQ+, youth, reproductive health and medical organizations, including the Endocrine Society, to intervene in an appeal of its decision that minors under age 16 likely could not give informed consent for pubertal suppression.

Plastics pose threat to human health

Plastics contain and leach hazardous chemicals, including endocrine-disrupting chemicals (EDCs) that threaten human health. An authoritative new report, Plastics, EDCs, & Health, from the Endocrine Society and the IPEN (International Pollutants Elimination Network), presents a summary of international research on the health impacts of EDCs and describes the alarming health effects of widespread contamination from EDCs in plastics.

Pervasive plastics increase exposure to harmful chemicals

The Endocrine Society and IPEN will release a comprehensive joint report Dec. 15 on endocrine-disrupting chemicals in plastics and the threat they pose to public health. Experts will share highlights from the report during a virtual news conference Dec. 15.

Endocrine Society urges Congress to increase funding for NIH

The Endocrine Society—the world’s largest professional organization for endocrine scientists and physicians—is calling on Congress to pass the House Labor-HHS spending bill to ensure health agencies are funded before the start of Fiscal Year 2021 and to avoid the tumult and disruption of a continuing resolution and potential government shutdowns.

Endocrine Society opposes Administration’s effort to roll back protections for transgender health

The Endocrine Society is alarmed by the Administration’s proposed rule to roll back protections for transgender individuals and narrow the scope of the Affordable Care Act (ACA), especially during the COVID-19 pandemic, when everyone needs access to health care. The Society calls on the Administration to maintain access to care protections for all, particularly vulnerable populations.

Heart attack, stroke risk declines among people with diabetes

The rate of heart attacks, strokes and other cardiovascular complications has improved among people with diabetes over the past 20 years, narrowing the gap in cardiovascular mortality rates between individuals with and without diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

Study suggests marijuana may impair female fertility

Female eggs exposed to THC, the psychoactive ingredient in marijuana, have an impaired ability to produce viable embryos, and are significantly less likely to result in a viable pregnancy, according to an animal study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting. The abstract will be published in the Journal of the Endocrine Society.

Individuals taking class of steroid medications at high risk for COVID-19

Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according to a new editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

Liraglutide can help adolescents with obesity manage their weight

Liraglutide 3.0 mg, approved by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity to help adults with obesity manage their weight, appears to help adolescents too, according to an industry-sponsored randomized controlled trial. The study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a supplemental issue of the Journal of the Endocrine Society.

Survey finds physicians struggle to communicate positive prognosis to thyroid cancer patients

Despite excellent prognosis with most thyroid cancers, many newly diagnosed patients have cancer-related worry, and physicians vary in their responses to patients’ worry, according to new research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

First FDA-approved drug for thyroid eye disease effective regardless of age, gender

Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction

Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Unconscious food cravings may make bariatric surgery less effective for people with extreme obesity

Patients with extreme obesity are prone to unconscious food impulses and cravings that may make it challenging for them to maintain weight loss after bariatric surgery, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Coconut oil reduces features of metabolic syndrome in obese females, animal study finds

Obese females that ate a small amount of coconut oil daily, even as part of a high-fat diet, had decreased features of metabolic syndrome, a cluster of risk factors that raise the chances of developing diabetes, heart disease and stroke, an animal study finds. The study results were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Poor fitness may impede long-term success in weight loss program

People who are very out of shape when they begin a behavioral weight loss program lose less weight in the long term than those who are more fit, suggests a new study that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Wearable delivery device allows patients with type 2 diabetes to safely use more affordable insulin option

Adults with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin (RHI) in a wearable, patch-like insulin delivery device called V-Go®, a new study finds. Results of the randomized controlled study—which was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society—suggest “a more affordable option” for insulin therapy than newer insulin types, the researchers said.

Most internists-in-training feel ill-equipped to treat obesity

Most resident physicians training in internal medicine do not feel adequately prepared to manage obesity in their patients, a new survey from a California residency program finds. The results were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Hypothyroidism patients cite effectiveness in choosing alternative to standard therapy

Three in four hypothyroidism patients who chose desiccated thyroid extract (DTE) over the standard therapy said this option was more effective than other thyroid hormone medications, according to an analysis of comments in online patient forums accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Two types of diabetes drugs similarly effective in reducing heart and kidney disease

Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Thyroid hormone use may raise death risk in older adults

Thyroid hormone replacement therapy in older adults is associated with a higher risk of death compared with no treatment, a large study finds. The study results were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Broken bone location can have significant impact on long-term health

In older individuals, the location of a broken bone can have significant impacts on long-term health outcomes, according to research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Fracking chemical may interfere with male sex hormone receptor

A chemical used in hydraulic fracturing, commonly called fracking, has the potential to interfere with reproductive hormones in men, according to research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Technology use by adults with type 1 diabetes lower among African Americans, Hispanics

Continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) devices are known to improve outcomes in patients with type 1 diabetes (T1D), yet African American and Hispanic patients face barriers to the use of these devices, according to results of a small single-center retrospective study. The results of the ENDO 2020 abstract will be published in the Journal of the Endocrine Society.